Disease Modification in Psoriasis Through Early IL-17 Inhibitor Intervention: A Retrospective Cohort Study

This dataset contains seven supplementary tables enabling assessment of the disease-modifying effects of early IL-17A inhibitor intervention on psoriasis in a real-world cohort. Table 1 presents baseline laboratory parameters stratified by disease duration:USDD: Psoriasis duration≤1 year，LDD1:Psoriasis duration>1 year;SDD:Psoriasis duration≤2 year,LDD2:Psoriasis duration>2 year. Tables 2-3 identify predictors of PASI 100 achievement at 4 and 52 weeks via logistic regression, demonstrating that shorter disease duration significantly increases the likelihood of achieving PASI 100 at both timepoints. Table 4 compares baseline characteristics and discontinuation rates by recurrence status, showing significantly longer mean disease duration and higher discontinuation rates in the recurrence group. Table 5 establishes predictors of relapse through logistic regression, revealing that each additional year of disease duration increases relapse risk by 3% (OR=1.03, 95%CI=1.007-1.054, p=0.01). Table 6 examines relapse after IL-17A discontinuation in ultra-short disease duration (USDD: Psoriasis duration≤1 year) versus long duration (LDD1:Psoriasis duration>1 year): After adjusting for baseline PASI, BSA, and other confounders, USDD showed 78.8% lower relapse risk (OR=0.212, 95%CI=0.055-0.826, p=0.025). Table 7 compares short disease duration (SDD:Psoriasis duration≤2 year) versus long duration (LDD2:Psoriasis duration>2 year): SDD was associated with 70.5% reduced relapse risk (OR=0.295, 95%CI=0.099-0.874, p=0.028) after similar adjustments.

本数据集包含7份补充表格，用以评估真实世界队列中早期白细胞介素17A（IL-17A）抑制剂干预对银屑病的疾病修饰效应。表1展示了按疾病时长分层的基线实验室参数，其中USDD定义为银屑病病程≤1年，LDD1定义为银屑病病程>1年；SDD定义为银屑病病程≤2年，LDD2定义为银屑病病程>2年。表2至表3通过逻辑回归分析了4周与52周时达到银屑病面积与严重性指数（PASI, Psoriasis Area and Severity Index）100的预测因素，结果显示更短的疾病时长可显著提升两个时间点下达到PASI 100的概率。表4对比了按复发状态分层的基线特征与停药率，结果显示复发组的平均疾病时长显著更长，停药率也更高。表5通过逻辑回归确立了复发的预测因素，结果显示每增加1年病程，复发风险升高3%（优势比OR=1.03，95%置信区间CI=1.007-1.054，p=0.01）。表6分析了超短病程（USDD：银屑病病程≤1年）与长病程（LDD1：银屑病病程>1年）患者在停用IL-17A抑制剂后的复发情况：在校正基线PASI、体表面积（BSA, Body Surface Area）及其他混杂因素后，USDD组的复发风险降低78.8%（OR=0.212，95%CI=0.055-0.826，p=0.025）。表7对比了短病程（SDD：银屑病病程≤2年）与长病程（LDD2：银屑病病程>2年）患者的情况：经类似校正后，SDD组的复发风险降低70.5%（OR=0.295，95%CI=0.099-0.874，p=0.028）。